Key takeaways
- Two medical technology businesses reportedly agreed on merger economics
- A leadership dispute ended negotiations over the $34 billion combination
- The failed deal demonstrates how corporate control shapes mergers
Two medical technology companies reportedly agreed on the financial terms of a $34 billion merger. They had negotiated ownership, valuations and even a multibillion-dollar payment. But the transaction fell apart over a question neither side would compromise on: who would become CEO?
The proposed combination involved Johnson & Johnson's orthopaedics business, DePuy Synthes, and British medical equipment manufacturer Smith & Nephew. According to an October 23 Financial Times investigation, negotiations collapsed just weeks before a planned announcement.
It was a reminder that even enormous corporate mergers depend on decisions that cannot always be settled through financial calculations.
A $34 Billion Deal With Almost Everything Agreed
Smith & Nephew approached Johnson & Johnson earlier in 2026 about combining its business with DePuy Synthes, one of the world's largest manufacturers of artificial joints and orthopaedic equipment.
The proposed transaction valued the J&J division at approximately $22 billion, compared with Smith & Nephew's roughly $12.6 billion stock-market valuation.
Under the reported structure, J&J shareholders would have owned 50.1% of the combined company, giving them a narrow majority. Smith & Nephew shareholders would have controlled the remaining 49.9%.
Smith & Nephew would also have arranged approximately $10 billion in debt financing to fund a payment to J&J, helping balance the transaction's different business valuations.
The transaction could have united complementary hip and knee replacement portfolios while giving both businesses greater scale.
For Smith & Nephew, which had faced slowing growth and shareholder pressure, the combination offered a potentially transformative alternative to its existing strategy.
But as other abandoned mergers illustrate, financial logic does not guarantee agreement on the final transaction.
The CEO Who Left in 2019 Returned to the Negotiating Table
The disagreement centered on two executives: Namal Nawana and Deepak Nath.
Nawana had served as Smith & Nephew's CEO for approximately 18 months before leaving in 2019 following a compensation dispute. Six years later, he joined J&J to lead DePuy Synthes through its planned separation.
J&J wanted Nawana to become chief executive of the combined company. Smith & Nephew, however, insisted that its current CEO, Deepak Nath, retain the top position, according to people familiar with the negotiations.
Chairman Rupert Soames reportedly made Nath's appointment a condition of the deal.
The dispute demonstrates why corporate governance can determine the outcome of transactions worth billions.
A CEO influences strategy, executive appointments, investment priorities and post-merger integration. Even when shareholders agree on ownership percentages, the identity of the person exercising day-to-day authority can remain contentious.
That question becomes especially difficult when two management teams have competing visions for a business.
What Happens After a $34 Billion Merger Fails?
Johnson & Johnson had already announced plans to separate DePuy Synthes in October 2025, with the business generating approximately $9.2 billion in 2024 sales.
Following the failed negotiations, J&J indicated that it was leaning toward a standalone spinoff instead.
Smith & Nephew faces a different challenge: improving performance independently while answering shareholders who may question whether rejecting the proposed leadership structure sacrificed a valuable strategic opportunity.
The episode reflects the importance of shareholder influence and board-level control when corporate strategies collide.
It also shows why a seemingly attractive takeover proposal can fail before investors ever receive a formal offer.
